EAM
IMMX icon

Eventide Asset Management’s Immix Biopharma IMMX Stock Holding History

Eventide Asset Management’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.1M Buy
3,891,019
+1,342,000
+53% +$12.4M 0.54% 60
2026
Q1 		$23.2M Hold
2,549,019
– – 0.38% 90
2025
Q4 		$13.3M Buy
+2,549,019
New +$10.5M 0.21% 127

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Eventide Asset Management's IMMX Position: Q2 2026 in Review

Eventide Asset Management increased its Immix Biopharma (IMMX) stake by 53% in Q2 2026, buying an estimated $12.4M and bringing the position to 3,891,019 shares worth $40.1M. The position accounts for 0.54% of the portfolio, ranked #60.

Eventide Asset Management first reported a position in IMMX in Q4 2025 and has held it in 3 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Eventide Asset Management held 3,891,019 shares of Immix Biopharma worth $40.1M as of Q2 2026.
  • Eventide Asset Management bought 1,342,000 Immix Biopharma shares in Q2 2026, an estimated $12.4M.
  • Immix Biopharma made up 0.54% of Eventide Asset Management's portfolio in Q2 2026, its #60 holding.
  • Eventide Asset Management first reported a position in Immix Biopharma in Q4 2025 and has held it in 3 quarters since.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.